{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 0, "source_chunk_idxs": [0], "num_tokens": 479, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\nAbout\nWho We Are\nJournal Membership\nContact Us\nDevelopment History\nLatest News\nJournals\nInformation\nEditorial Policies\nEditorial Process\nOpen Access Policy\nResearch and Publication Ethics\nArticle Processing Charges\nAdvertising Policy\nBooks\nCareers\nLogin\nHome\nAbout\nOverview\nAbout the Journal\nAims &amp; Scope\nEditorial Board\nReviewer Board\nIndexing &amp; Archiving\nAcademic Supporter\nPartners\nJournal History\nArticles\nOnline First\nCurrent Issue\nArchive\nColumn\nColumn\nEdit a Special Issue\nFor Authors\nInstructions for Authors\nArticle Processing Charge\nEditorial Process\nExchanges\nWebinars\nEditorial Office\nSubmissions\nSearch Article Article Special Issue Article Types Article Types Year - Volume Issue Pages - Search\nAccScience Publishing\n/\nAN\n/\nOnline First\n/ DOI: 10.36922/AN025160040\nSubmit to AN\nApply for Special Issue\nCite this article 55 Download 2179 Views Related Info Links\nGoogle Scholar\nMore by Authors Links\nMohammad Shahangir Biswas\nJournal Browser Volume | Year Issue Search\nForthcoming Issue\nCurrent Issue\nView All\nNews and Announcements\nView All\nREVIEW ARTICLE\nNeurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\nMd. Nazmul Hossain\n1\n, Rabeya Sultana Badhon\n1\n, Mohammad Shahangir Biswas\n2,3*\n, Munna Kumar Podder\n1\n, Suronjit Kumar Roy\n1\n, Rubait Hasan\n1\n, Md. Moyen Uddin Pk\n4\nShow Less\n1\nDepartment of Biochemistry and Biotechnology, Khwaja Yunus Ali University, Sirajganj , Bangladesh\n2\nDepartment of Biochemistry and Biotechnology, University of Science and Technology Chittagong, Chittagong , Bangladesh\n3\nDepartment of Public Health, Daffodil International University, Dhaka , Bangladesh\n4\nInstitute of Biological Sciences, Rajshahi University, Rajshahi , Bangladesh\nAdvanced Neurology\n, 025160040\nhttps://doi.org/10.36922/AN025160040\nReceived: 20 April 2025 |  Revised: 4 August 2025 |  Accepted: 13 August 2025 |  Published online: 29 August 2025\n\u00a9 2025 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License\n( https://creativecommons.org/licenses/by/4.0/ )\nDownload PDF\nXML\nCite\nAbstract", "doc_items_refs": ["#/texts/1", "#/texts/2", "#/texts/3", "#/texts/4", "#/texts/5", "#/texts/6", "#/texts/7", "#/texts/8", "#/texts/9", "#/texts/10", "#/texts/11", "#/texts/12", "#/texts/13", "#/texts/14", "#/texts/15", "#/texts/16", "#/texts/17", "#/texts/18", "#/texts/19", "#/texts/20", "#/texts/21", "#/texts/22", "#/texts/23", "#/texts/24", "#/texts/25", "#/texts/26", "#/texts/27", "#/texts/28", "#/texts/29", "#/texts/30", "#/texts/31", "#/texts/32", "#/texts/33", "#/texts/34", "#/texts/35", "#/texts/36", "#/texts/37", "#/texts/38", "#/texts/39", "#/texts/40", "#/texts/41", "#/texts/42", "#/texts/43", "#/texts/44", "#/texts/45", "#/texts/46", "#/texts/47", "#/texts/48", "#/texts/49", "#/texts/50", "#/texts/51", "#/texts/52", "#/texts/53", "#/texts/54", "#/texts/55", "#/texts/56", "#/texts/57", "#/texts/58", "#/texts/59", "#/texts/60", "#/texts/61", "#/texts/62", "#/texts/63", "#/texts/64", "#/texts/65", "#/texts/66", "#/texts/67", "#/texts/68", "#/texts/69", "#/texts/70", "#/texts/71", "#/texts/72", "#/texts/73", "#/texts/74", "#/texts/75", "#/texts/76", "#/texts/77", "#/texts/78", "#/texts/79", "#/texts/80", "#/texts/81", "#/texts/82", "#/texts/83", "#/texts/84", "#/texts/85", "#/texts/86", "#/texts/87", "#/texts/88", "#/texts/89", "#/texts/90", "#/texts/91", "#/texts/92", "#/texts/93", "#/texts/94", "#/texts/95", "#/texts/96", "#/texts/97"], "page_nos": [], "uuid": "a1691dca-b3b7-4c93-95da-4531c9528d40"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 1, "source_chunk_idxs": [1], "num_tokens": 499, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\nAlzheimer's disease (AD) is a progressive neurodegenerative disorder responsible for 50-75% of dementia cases worldwide, primarily affecting individuals over 65 years of age. It is characterized by cognitive decline, memory loss, and behavioral abnormalities. Key pathological features include extracellular \u03b2-amyloid (A\u03b2) plaques, intracellular neurofibrillary tangles of hyperphosphorylated tau protein, mitochondrial dysfunction, and cholinergic system impairment. Despite extensive research, the precise etiology remains unclear, and current treatments only alleviate symptoms without halting disease progression. A comprehensive literature review was conducted using peer-reviewed articles from PubMed, Scopus, and Google Scholar, emphasizing recent studies on molecular mechanisms, risk factors, diagnostics, and therapies. Major pathogenic mechanisms identified include oxidative stress, tau hyperphosphorylation, A\u03b2 aggregation, and synaptic degeneration. Non-modifiable risk factors such as aging, genetic mutations in amyloid precursor protein, phosphatidylinositol-binding clathrinid assembly protein, presenilin 1/2, and the apolipoprotein E \u03b54 allele play significant roles, whereas modifiable risks involve lifestyle factors and comorbidities such as diabetes. Diagnostic advancements highlight the promise of blood-based biomarkers, although current practices rely heavily on cerebrospinal fluid markers and neuroimaging. Approved pharmacological interventions, including cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists, provide limited symptomatic relief. Ongoing research into A\u03b2- and tau-targeted therapies has yielded mixed results. In addition, novel approaches such as tripartite motif-containing protein 2-mediated tau clearance and deep cervical lymphatic-venous anastomosis are being explored for their potential in targeting intracellular aggregates and enhancing brain waste clearance. AD emerges as a multifactorial condition driven by a complex interplay of biological, genetic, and environmental factors. Although substantial progress has been made in understanding its pathophysiology, effective disease-modifying therapies remain elusive. Continued advances in biomarker discovery and personalized therapeutic strategies offer hope for improved early detection and targeted treatment approaches.", "doc_items_refs": ["#/texts/98"], "page_nos": [], "uuid": "1021922f-6536-4732-9a58-8eb1ed59cfcd"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 2, "source_chunk_idxs": [2], "num_tokens": 503, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\nKeywords Alzheimer's disease Neurodegeneration Amyloid-beta Mitochondrial dysfunction Biomarkers Funding None. Conflict of interest The authors declare that they have no competing interests.\nReferences\n1. Rahman MR, Tajmim A, Ali M, Sharif M. Overview and current status of Alzheimer's disease in Bangladesh.\nJ Alzheimers Dis Rep.\n2017;1(1):27-42. doi: 10.3233/ADR-170012\n1. Bird TD. Alzheimer disease overview.\nGeneReviews\u00ae\n. Seattle, WA: University of Washington, Seattle; 2018.\n1. Gustavsson A, Norton N, Fast T,\net al\n. Global estimates on the number of persons across the Alzheimer's disease continuum.\nAlzheimers Dement\n. 2023;19(2):658-670. doi: 10.1002/alz.12694.\n1. Atri A. The Alzheimer's disease clinical spectrum: Diagnosis and management.\nMed Clin North Am\n. 2019;103(2):263-293. doi: 10.1016/j.mcna.2018.10.009\n1. Budson AE. Understanding memory dysfunction.\nNeurologist\n. 2009;15(2):71-79. doi: 10.1097/NRL.0b013e318188040d\n1. Huynh RA, Mohan C. Alzheimer's disease: Biomarkers in the genome, blood, and cerebrospinal fluid.\nFront Neurol\n. 2017;8:102. doi: 10.3389/fneur.2017.00102\n1. Wang W, Zhao F, Ma X, Perry G, Zhu X. Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: Recent advances.\nMol Neurodegener\n. 2020;15:30. doi: 10.1186/s13024-020-00376-6\n1. Mary A, Eysert F, Checler F, Chami M. Mitophagy in Alzheimer's disease: Molecular defects and therapeutic approaches.\nMol Psychiatry\n. 2023;28(1):202-216. doi: 10.1038/s41380-022-01631-6", "doc_items_refs": ["#/texts/99", "#/texts/100", "#/texts/101", "#/texts/102", "#/texts/103", "#/texts/104", "#/texts/105", "#/texts/106", "#/texts/107", "#/texts/108"], "page_nos": [], "uuid": "26378396-ae39-4a1e-92ec-9fd4573ba874"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 3, "source_chunk_idxs": [3], "num_tokens": 469, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. John A, Reddy PH. Synaptic basis of Alzheimer's disease: Focus on synaptic amyloid beta, P-tau and mitochondria.\nAgeing Res Rev\n. 2021;65:101208. doi: 10.1016/j.arr.2020.101208\n1. Calvo-Rodriguez M, Bacskai BJ. Mitochondria and calcium in Alzheimer's disease: From cell signaling to neuronal cell death.\nTrends Neurosci\n. 2021;44(2):136-151. doi: 10.1016/j.tins.2020.10.004\n1. Rifat MMH, Parvin MN, Hossain ML. Pattern and treatment of Alzheimer's disease at different health care levels in Bangladesh: A hospital based survey.\nInt J Community Med Public Health\n. 2025;12(2):719. doi: 10.18203/2394-6040.ijcmph20250302\n1. Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of early Alzheimer's disease: Clinical practice in 2021.\nJ Prev Alzheimers Dis\n. 2021;8(3):371-386. doi: 10.14283/jpad.2021.23\n1. Bonakdarpour B, Takarabe C. Brain networks, clinical manifestations, and neuroimaging of cognitive disorders: The role of computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and other advanced neuroimaging tests.\nClin Geriatr Med\n. 2023;39(1):45-65. doi: 10.1016/j.cger.2022.07.004\n1. Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: An update.\nJ Cent Nerv Syst Dis\n. 2020;12:1-15. doi: 10.1177/1179573520907397", "doc_items_refs": ["#/texts/109", "#/texts/110", "#/texts/111", "#/texts/112", "#/texts/113", "#/texts/114"], "page_nos": [], "uuid": "d2f5144e-3141-4c92-a644-2aaa1fb66a7b"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 4, "source_chunk_idxs": [4], "num_tokens": 500, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Li J, Haj Ebrahimi A, Ali AB. Advances in therapeutics to alleviate cognitive decline and neuropsychiatric symptoms of Alzheimer's disease.\nInt J Mol Sci\n. 2024;25(10):5169. doi: 10.3390/ijms25105169\n1. Monteiro AR, Barbosa DJ, Remi\u00e3o F, Silva R. Alzheimer's disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs.\nBiochem Pharmacol\n. 2023;211:115522. doi: 10.1016/j.bcp.2023.115522\n1. Schelterns P, Feldman H, Scarpini E. Treatment of Alzheimer's disease: Current status and new perspectives.\nLancet Neurol.\n2003;2:539-547. doi: 10.1016/s1474-4422(03)00502-7\n1. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer's disease.\nNature.\n2015;1:15056. doi: 10.1038/nrdp.2015.56\n1. Terry AV Jr., Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development.\nJ Pharmacol Exp Ther\n. 2003;306:821-827. doi: 10.1124/jpet.102.041616\n1. Firth J, Solmi M, Wootton RE,\net al\n. A meta-review of \"lifestyle psychiatry\": The role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders.\nWorld Psychiatry.\n2020;19(3):360-380. doi: 10.1002/wps.20773\n1. Vasser R. BACE1: The beta-secretase enzyme in Alzheimer's disease.\nJ Mol Neurosci.\n2004;23(1-2):105-113. doi: 10.1385/JMN:23:1-2:105", "doc_items_refs": ["#/texts/115", "#/texts/116", "#/texts/117", "#/texts/118", "#/texts/119", "#/texts/120", "#/texts/121"], "page_nos": [], "uuid": "f14b7a7f-d6f9-4f55-9543-7c7bbd1563c5"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 5, "source_chunk_idxs": [5], "num_tokens": 506, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Surguchov A, Emamzadeh F, Titova M, Surguchov AA. Controversial properties of amyloidogenic proteins and peptides: New data in the COVID era.\nBiomedicines.\n2023;11:1215. doi: 10.3390/biomedicines11041215\n1. Seeman P, Seeman N. Alzheimer's disease: \u03b2-amyloid plaque formation in human brain.\nSynapse\n. 2011;65(12):1289-1297. doi: 10.1002/SYN.20957\n1. Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric A\u03b2-induced synaptic dysfunction in Alzheimer's disease.\nMol Neurodegener.\n2014;9:48. doi: 10.1186/1750-1326-9-48\n1. Chen JX, Yan SS. Role of mitochondrial amyloid-beta in Alzheimer's disease.\nJ Alzheimers Dis.\n2010;20(Suppl 2):569-578. doi: 10.3233/JAD-2010-100357\n1. Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease.\nHum Mol Genet.\n2010;19:R12-R20. doi: 10.1093/hmg/ddq160\n1. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease.\nNature.\n1999;399:A23-A31. doi: 10.1038/399a023\n1. Sherrington R, Rogaev E, Liang Y,\net al\n. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease.\nNature.\n1995;345:754-760. doi: 10.1038/375754a0\n1. Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: Advances in genetics, pathophysiology, and therapeutic approaches.\nLancet Neurol.\n2021;20(1):68-80. doi: 10.1016/S1474-4422(20)30412-9", "doc_items_refs": ["#/texts/122", "#/texts/123", "#/texts/124", "#/texts/125", "#/texts/126", "#/texts/127", "#/texts/128", "#/texts/129"], "page_nos": [], "uuid": "c1b9a28e-50b0-46d6-abf3-487192c0296b"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 6, "source_chunk_idxs": [6], "num_tokens": 507, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Sajjad R, Arif R, Shah AA, Manzoor I, Mustafa G. Pathogenesis of Alzheimer's disease: Role of amyloid-beta and hyperphosphorylated tau protein.\nIndian J Pharm Sci\n. 2018;80(4):581-591. doi: 10.4172/PHARMACEUTICAL-SCIENCES.1000397\n1. Das BC, Pradhan S, Ojha DP, Das A, Hosmane NS, Das S. The role of tau protein in diseases.\nAnn Adv Chem\n. 2018;2:001-016. doi: 10.29328/JOURNAL.AAC.1001010\n1. Mietelska-Porowska A, Wasik U, Goras M, Filipek A, Niewiadomska G. Tau protein modifications and interactions: Their role in function and dysfunction.\nInt J Mol Sci.\n2014;15(3):4671-4713. doi: 10.3390/ijms15034671\n1. Iqbal K, Gong CX, Liu F. Hyperphosphorylation-induced tau oligomers.\nFront Neurol\n. 2013;4:112. doi: 10.3389/FNEUR.2013.00112\n1. Gong CX, Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease.\nCurr Med Chem\n. 2008;15(23):2321-2328. doi: 10.2174/092986708785909111\n1. Lee HG, Perry G, Moreira PI,\net al\n. Tau phosphorylation in Alzheimer's disease: Pathogen or protector?\nTrends Mol Med.\n2005;11(4):164-169. doi: 10.1016/j.molmed.2005.02.008\n1. Neddens J, Temmel M, Flunkert S,\net al\n. Phosphorylation of different tau sites during progression of Alzheimer's disease.\nActa Neuropathol Commun.\n2018;6(1):52. doi: 10.1186/s40478-018-0557-6", "doc_items_refs": ["#/texts/130", "#/texts/131", "#/texts/132", "#/texts/133", "#/texts/134", "#/texts/135", "#/texts/136"], "page_nos": [], "uuid": "5c1d85bf-8d3f-4737-8589-d2eaafbc8827"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 7, "source_chunk_idxs": [7], "num_tokens": 435, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Zhao H, Chang R, Che H,\net al\n. Hyperphosphorylation of tau protein by calpain regulation in retina of Alzheimer's disease transgenic mouse.\nNeurosci Lett\n. 2013;551:12-16. doi: 10.1016/J.NEULET.2013.06.026\n1. Lee VMY, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies.\nAnnu Rev Neurosci\n. 2001;24:1121-1159. doi: 10.1146/ANNUREV.NEURO.24.1.1121\n1. Kametani F, Hasegawa M. Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer's disease.\nFront Neurosci\n. 2018;12:25. doi: 10.3389/FNINS.2018.00025\n1. Schwarthoff S, Tischer N, Sager H,\net al\n. Evaluation of \u03b3-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.\nBioorg Med Chem.\n2021;46:116355. doi: 10.1016/j.bmc.2021.116355\n1. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis.\nExp Neurol\n. 2000;163:495-529. doi: 10.1006/exnr.2000.7397\n1. Lecrux C, Sandoe CH, Neupane S,\net al\n. Impact of altered cholinergic tones on the neurovascular coupling response to whisker stimulation.\nJ Neurosci.\n2017;37:1518-1531. doi: 10.1523/JNEUROSCI.1784-16.2016", "doc_items_refs": ["#/texts/137", "#/texts/138", "#/texts/139", "#/texts/140", "#/texts/141", "#/texts/142"], "page_nos": [], "uuid": "2e141a3e-6032-4ca2-a9fa-cf9e97531626"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 8, "source_chunk_idxs": [8], "num_tokens": 480, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Frinchi M, Scaduto P, Cappello F, Belluardo N, Mud\u00f2 G. Heat shock protein (Hsp) regulation by muscarinic acetylcholine receptor (mAChR) activation in the rat hippocampus.\nJ Cell Physiol\n. 2018;233(8):6107-6116. doi: 10.1002/JCP.26454\n1. Hu Y, Qu Z, Cao S,\net al\n. Directed differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells.\nJ Neurosci Methods.\n2016;266:42-49. doi: 10.1016/j.jneumeth.2016.03.017\n1. Latina V, Caioli S, Zona C,\net al\n. NGF-dependent changes in ubiquitin homeostasis trigger early cholinergic degeneration in cellular and animal AD-model.\nFront Cell Neurosci\n. 2018;12:487 doi: 10.3389/FNCEL.2018.00487\n1. Eivani M, Alijanpour S, Arefian E, Rezayof A. Corticolimbic analysis of microRNAs and protein expressions in scopolamine-induced memory loss under stress.\nNeurobiol Learn Mem.\n2019;164:107065\n.\ndoi: 10.1016/j.nlm.2019.107065\n1. Cafe-Mendes C, Garay-Malpartida H, Malta MB,\net al\n. Chronic nicotine treatment decreases LPS signaling through NF-\u03baB and TLR-4 modulation in the hippocampus.\nNeurosci Lett.\n2017;636:218-224. doi: 10.1016/j.neulet.2016.10.056\n1. Yegla B, Parikh V. Developmental suppression of forebrain trkA receptors and attentional capacities in aging rats: A longitudinal study.\nBehav Brain Res.\n2017;335:111-121. doi: 10.1016/j.bbr.2017.08.017", "doc_items_refs": ["#/texts/143", "#/texts/144", "#/texts/145", "#/texts/146", "#/texts/147", "#/texts/148"], "page_nos": [], "uuid": "37015a41-2220-4b95-99aa-0459c6fae6af"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 9, "source_chunk_idxs": [9], "num_tokens": 448, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Martinez-Rubio C, Paulk AC, Mcdonald EJ, Widge AS, Eskandar EN. Multimodal encoding of novelty, reward, and learning in the primate nucleus basalis of meynert.\nJ Neurosci.\n2018;38:1942-1958. doi: 10.1523/JNEUROSCI.2021-17.2017\n1. Chen H, McCaffery J, Cell DC. Mitochondrial fusion protects against neurodegeneration in the cerebellum.\nCell.\n2007;130:548-562. doi: 10.1016/j.cell.2007.06.026\n1. Guo L, Tian J, Du H. Mitochondrial dysfunction and synaptic transmission failure in Alzheimer's disease.\nJ Alzheimers Dis.\n2017;57(4):1071-1086. doi: 10.3233/JAD-160702\n1. Garcia-Casas P, Rossini M, Filadi R, Pizzo P. Mitochondrial Ca2+ signaling and Alzheimer's disease: Too much or too little?\nCell Calcium\n. 2023;113:102757. doi: 10.1016/J.CECA.2023.102757\n1. Hadi F, Mortaja M, Hadi Z. Calcium (Ca2+) hemostasis, mitochondria, autophagy, and mitophagy contribute to Alzheimer's disease as early moderators.\nCell Biochem Funct\n. 2024;42(5):e4085. doi: 10.1002/CBF.4085\n1. Good PF, Perl DP, Bierer LM, Schmeidler J. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: A laser microprobe (LAMMA) study.\nAnn Neurol\n. 1992;31(3):286-292. doi: 10.1002/ANA.410310310", "doc_items_refs": ["#/texts/149", "#/texts/150", "#/texts/151", "#/texts/152", "#/texts/153", "#/texts/154"], "page_nos": [], "uuid": "45008c44-a6dd-4e0b-af98-73465a4c6f11"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 10, "source_chunk_idxs": [10], "num_tokens": 488, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Smith MA, Harris PLR, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals.\nProc Natl Acad Sci U S A\n. 1997;94(18):9866-9868. doi: 10.1073/PNAS.94.18.9866\n1. Oteiza PI. A mechanism for the stimulatory effect of aluminum on iron-induced lipid peroxidation.\nArch Biochem Biophys.\n1994;308:374-379. doi: 10.1006/abbi.1994.1053\n1. Colton CA, Gilbert DL. Production of superoxide anions by a CNS macrophage, the microglia.\nFEBS Lett.\n1987;223(2):284-288. doi: 10.1016/0014-5793(87)80305-8\n1. Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence of neuronal oxidative damage in Alzheimer's disease.\nAm J Pathol\n. 1996;149(1):21-28.\n1. Smith MA, Harris PLR, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease.\nJ Neurosci.\n1997;17:2653-2657. doi: 10.1523/JNEUROSCI.17-08-02653.1997\n1. Davis RE, Miller S, Herrnstadt C,\net al\n. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease.\nProc Natl Acad Sci U S A\n. 1997;94(9):4526-4531. doi: 10.1073/PNAS.94.9.4526\n1. Parker WD Jr., Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer's disease.\nNeurology\n. 1990;40(8):1302-1303. doi: 10.1212/WNL.40.8.1302", "doc_items_refs": ["#/texts/155", "#/texts/156", "#/texts/157", "#/texts/158", "#/texts/159", "#/texts/160", "#/texts/161"], "page_nos": [], "uuid": "927b400c-fe1c-4c5c-af7e-cfbfde619772"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 11, "source_chunk_idxs": [11], "num_tokens": 454, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Calderon-Garcidue\u00f1as A, Duyckaerts C.\nAlzheimer Disease\n. Netherlands: Elsevier; Available from: https://www.sciencedirect.com/science/article/pii/ b9780128023952000237 [Last accessed on 2025 Apr 13].\n1. Dubois B, Von Arnim CAF, Burnie N, Bozeat S, Cummings J. Biomarkers in Alzheimer's disease: Role in early and differential diagnosis and recognition of atypical variants.\nAlzheimers Res Ther.\n2023;15(1):175. doi: 10.1186/s13195-023-01314-6\n1. Neugroschl J, Davis KL. Biological markers in Alzheimer disease.\nAm J Geriatr Psychiatry\n. 2002;10:660-677. doi: 10.1097/00019442-200211000-00005\n1. Borroni B, Luca MD, Padovani A. Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful?\nEur J Pharmacol.\n2006;545:73-80. doi: 10.1016/j.ejphar.2006.06.023\n1. Fiandaca MS, Mapstone ME, Cheema AK, Federoff HJ. The critical need for defining preclinical biomarkers in Alzheimer's disease.\nAlzheimers Dement.\n2014;10(3 Suppl):S196-S212. doi: 10.1016/j.jalz.2014.04.015\n1. Hampel H, Cummings J, Blennow K, Gao P, Jack CR Jr., Vergallo A. Developing the ATX(N) classification for use across the Alzheimer disease continuum.\nNat Rev Neurol.\n2021;17:580-589. doi: 10.1038/s41582-021-00520-w", "doc_items_refs": ["#/texts/162", "#/texts/163", "#/texts/164", "#/texts/165", "#/texts/166", "#/texts/167"], "page_nos": [], "uuid": "5678c75e-161a-4fc7-af23-c5255955c094"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 12, "source_chunk_idxs": [12], "num_tokens": 457, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Pillai JA, Bonner-Jackson A, Bekris LM, Safar J, Bena J, Leverenz JB. Highly elevated cerebrospinal fluid total tau level reflects higher likelihood of non-amnestic subtype of Alzheimer's disease.\nJ Alzheimers Dis.\n2019;70(4):1051-1058. doi: 10.3233/JAD-190519\n1. Ossenkoppele R, Mattsson N, Teunissen CE,\net al\n. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.\nNeurobiol Aging.\n2015;36(8):2340-2347. doi: 10.1016/j.neurobiolaging.2015.04.011\n1. Hansson O, Seibyl J, Stomrud E,\net al\n. CSF biomarkers of Alzheimer's disease concord with amyloid-\u03b2 PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.\nAlzheimers Dement\n. 2018;14:1470-1481. doi: 10.1016/j.jalz.2018.01.010\n1. Wattmo C, Blennow K, Hansson O. Cerebro-spinal fluid biomarker levels: Phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.\nBMC Neurol.\n2020;20(1):10. doi: 10.1186/s12883-019-1591-0\n1. Janelidze S, Zetterberg H, Mattsson N,\net al\n. CSF A\u03b242/A\u03b240 and A\u03b242/A\u03b238 ratios: Better diagnostic markers of Alzheimer disease.\nAnna Clin Transl Neurol.\n2016;3(3):154-165. doi: 10.1002/acn3.274", "doc_items_refs": ["#/texts/168", "#/texts/169", "#/texts/170", "#/texts/171", "#/texts/172"], "page_nos": [], "uuid": "c821d4af-a3e2-4bc7-8db0-b72dcc18b1a2"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 13, "source_chunk_idxs": [13], "num_tokens": 447, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Cruz De Souza L, Bertoux M, Funkiewiez A,\net al\n. Frontal presentation of Alzheimer's disease: A series of patients with biological evidence by CSF biomarkers.\nDement Neuropsychol\n. 2013;7(1):66-74. doi: 10.1590/S1980-57642013DN70100011\n1. Ashton NJ, Ea A, Benedet L,\net al\n. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease.\nEBioMedicine\n. 2022:76:103836. doi: 10.1016/j.ebiom.2022.103836\n1. Liu W, Lin H, He X,\net al\n. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment.\nTransl Psychiatry\n. 2020;10:125. doi: 10.1038/s41398-020-0801-2\n1. Mi\u00ec A-Alom\u00e0 M, Brinkmalm A, Ashton NJ,\net al\n. CSF synaptic biomarkers in the preclinical stage of Alzheimer disease and their association with MRI and PET: A cross-sectional study.\nNeurology\n. 2021;97(21):E2065-E2078. doi: 10.1212/WNL.0000000000012853\n1. Muszy\u0144ski P, Groblewska M, Kulczy\u0144ska-Przybik A, Ku\u0142akowska A, Mroczko B. YKL-40 as a potential biomarker and a possible target in therapeutic strategies of Alzheimer's disease.\nCurr Neuropharmacol\n. 2017;15(6):906-917. doi: 10.2174/1570159X15666170208124324", "doc_items_refs": ["#/texts/173", "#/texts/174", "#/texts/175", "#/texts/176", "#/texts/177"], "page_nos": [], "uuid": "7fb44cd0-9f9c-48a0-9b56-06fd18dbbf1e"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 14, "source_chunk_idxs": [14], "num_tokens": 483, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Olsson B, Lautner R, Andreasson U,\net al\n. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: A systematic review and meta-analysis.\nLancet Neurol\n. 2016;15:673-684. doi: 10.1016/S1474-4422(16)00070-3\n1. Zetterberg H, M\u00f6rtberg E, Song L,\net al\n. Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid \u03b2 levels in humans.\nPLoS One.\n2011;6(12):28263. doi: 10.1371/journal.pone.0028263\n1. Janelidze S, Stomrud E, Palmqvist S,\net al\n. Plasma \u03b2-amyloid in Alzheimer's disease and vascular disease.\nScie Rep.\n2016;6:26801. doi: 10.1038/srep26801\n1. Verberk IMW, Slot RE, Verfaillie SCJ,\net al\n. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes.\nAnn Neurol.\n2018;84(5):648-658. doi: 10.1002/ana.25334\n1. Nakamura A, Kaneko N, Villemagne V,\net al.\nHigh performance plasma amyloid-\u03b2 biomarkers for Alzheimer's disease.\nNature\n. 2018;554:249-254. doi: 10.1038/nature25456\n1. Ovod V, Ramsey KN, Mawuenyega KG,\net al\n. Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis.\nAlzheimers Dement\n. 2017;13(8):841-849. doi: 10.1016/J.JALZ.2017.06.2266\n1. Li QX, Berndt MC, Bush AI,\net al\n. Membrane-associated forms of the beta A4 amyloid protein precursor of Alzheimer's disease in human platelet and brain: Surface expression on the activated human.\nBlood\n. 1994;84:133-142.", "doc_items_refs": ["#/texts/178", "#/texts/179", "#/texts/180", "#/texts/181", "#/texts/182", "#/texts/183", "#/texts/184"], "page_nos": [], "uuid": "89e3fadb-064e-4470-9f51-971e6befde76"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 15, "source_chunk_idxs": [15], "num_tokens": 453, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Zetterberg H, Wilson D, Andreasson U,\net al\n. Plasma tau levels in Alzheimer's disease.\nAlzheimers Res Ther.\n2013;5(2):9. doi: 10.1186/alzrt163\n1. Mattsson N, Zetterberg H, Janelidze S,\net al\n. Plasma tau in Alzheimer disease.\nNeurology\n. 2016;87(17):1827-1835. doi: 10.1212/WNL.0000000000003246\n1. Mielke MM, Hagen CE, Wennberg AWV,\net al\n. Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the mayo clinic study on aging.\nJAMA Neurol\n. 2017;74:1073-1080. doi: 10.1001/jamaneurol.2017.1359\n1. Pase MP, Beiser AS, Himali JJ,\net al\n. Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes.\nJAMA Neurol\n. 2019;76(5):598-606. doi: 10.1001/JAMANEUROL.2018.4666\n1. Mielke M, Hagen C, Xu J,\net al\n. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau-and amyloid-positron emission tomography.\nAlzheimers Dement\n. 2018;14:989-997. doi: 10.1016/j.jalz.2018.02.013\n1. Yang CC, Chiu MJ, Chen TF, Chang HL, Liu BH, Yang SY. Assay of plasma phosphorylated tau protein (threonine 181) and total tau protein in early-stage Alzheimer's disease.\nJ Alzheimers Dis\n. 2018;61(4):1323-1332. doi: 10.3233/JAD-170810", "doc_items_refs": ["#/texts/185", "#/texts/186", "#/texts/187", "#/texts/188", "#/texts/189", "#/texts/190"], "page_nos": [], "uuid": "41c1e7c6-6704-44f9-88a4-66619b0ec88a"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 16, "source_chunk_idxs": [16], "num_tokens": 441, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Tatebe H, Kasai T, Ohmichi T,\net al\n. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: Pilot case-control studies including patients with Alzheimer's disease and down syndrome.\nMol Neurodegener.\n2017;12(1):63. doi: 10.1186/s13024-017-0206-8\n1. Khalil M, Teunissen CE, Otto M,\net al\n. Neurofilaments as biomarkers in neurological disorders- towards clinical application.\nNat Rev Neurol\n. 2024;20:269-287. doi: 10.1038/s41582-024-00955-x\n1. Weston PSJ, Poole T, Ryan NS,\net al\n. Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration.\nNeurology\n. 2017;89(21):2167-2175. doi: 10.1212/WNL.0000000000004667\n1. Yilmaz A, Blennow K, Hagberg L,\net al\n. Neurofilament light chain protein as a marker of neuronal injury: Review of its use in HIV-1 infection and reference values for HIV-negative controls.\nExpert Rev Mol Diagn\n. 2017;17(8):761-770. doi: 10.1080/14737159.2017.1341313\n1. Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer's Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease.\nJAMA Neurol\n. 2017;74(5):557-566. doi: 10.1001/jamaneurol.2016.6117", "doc_items_refs": ["#/texts/191", "#/texts/192", "#/texts/193", "#/texts/194", "#/texts/195"], "page_nos": [], "uuid": "2a9b983d-fc89-415d-9df5-c56f6a2d5ff4"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 17, "source_chunk_idxs": [17], "num_tokens": 504, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Minoshima S, Cross D, Thientunyakit T, Foster NL, Drzezga A. 18F-FDG PET imaging in neurodegenerative dementing disorders: Insights into subtype classification, emerging disease categories, and mixed dementia with copathologies.\nJ Nucl Med.\n2022;63:2S-12S. doi: 10.2967/jnumed.121.263194\n1. Graff-Radford J, Yong KXX, Apostolova LG,\net al\n. New insights into atypical Alzheimer's disease in the era of biomarkers.\nLancet Neurol.\n2021;20(3):222-234. doi: 10.1016/S1474-4422(20)30440-3\n1. Mecca AP, Chen MK, O'dell RS,\net al\n.\nIn vivo\nmeasurement of widespread synaptic loss in Alzheimer's disease with SV2A PET.\nAlzheimers Dement.\n2020;16(7):974-982. doi: 10.1002/alz.12097\n1. Clark CM, Pontecorvo MJ, Beach TG,\net al\n. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: A prospective cohort study.\nLancet Neurol\n. 2012;11:669-678. doi: 10.1016/S1474-4422(12)70142-4\n1. Wolk DA. Amyloid imaging in atypical presentations of Alzheimer's disease.\nCurr Neurol Neurosci Rep.\n2013;13(12):412. doi: 10.1007/s11910-013-0412-x\n1. Fleisher AS, Pontecorvo MJ, Devous MD Sr.,\net al\n. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes.\nJAMA Neurol.\n2020;77(7):829-839. doi: 10.1001/jamaneurol.2020.0528", "doc_items_refs": ["#/texts/196", "#/texts/197", "#/texts/198", "#/texts/199", "#/texts/200", "#/texts/201"], "page_nos": [], "uuid": "8d6730d1-dd3e-4122-a3e0-594619622173"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 18, "source_chunk_idxs": [18], "num_tokens": 475, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Ossenkoppele R, Pichet Binette A, Groot C,\net al\n. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.\nNat Med\n. 2022;28:2381-2387. doi: 10.1038/s41591-022-02049-x\n1. Strikwerda-Brown C, Hobbs DA, Gonneaud J,\net al\n. Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment.\nJAMA Neurol\n. 2022;79:975-985. doi: 10.1001/jamaneurol.2022.2379\n1. Samra A, Ramtahal J. Recurrent subacute visual loss presenting in a 52-year-recurrent subacute visual loss presenting in a 52-year.\nBrain\n. 2012;139(4):16-17. doi: 10.1093/BRAIN/AWW041\n1. Werry EL, Bright FM, Piguet O,\net al\n. Recent developments in TSPO PET imaging as a biomarker of neuroinflammation in neurodegenerative disorders.\nInt J Mol Sci\n. 2019;20:3161. doi: 10.3390/ijms2013316\n1. Vemuri P, Jack CR Jr. Role of structural MRI in Alzheimer's disease.\nAlzheimers Res Ther\n. 2010;2(4):23. doi: 10.1186/ALZRT47\n1. Liu S, Buch S, Chen Y,\net al\n. Susceptibility-weighted imaging: Current status and future directions.\nNMR Biomed\n. 2017;30(4):10. doi: 10.1002/nbm.3552\n1. Damoiseaux JS. Resting-state fMRI as a biomarker for Alzheimer's disease?\nAlzheimers Res Ther\n. 2012;4(3):8. doi: 10.1186/alzrt106", "doc_items_refs": ["#/texts/202", "#/texts/203", "#/texts/204", "#/texts/205", "#/texts/206", "#/texts/207", "#/texts/208"], "page_nos": [], "uuid": "ddacf6a7-8f02-41db-a81a-386243759cd1"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 19, "source_chunk_idxs": [19], "num_tokens": 466, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Stebbins GT, Murphy CM. Diffusion tensor imaging in Alzheimer's disease and mild cognitive impairment.\nBehav Neurol\n. 2009;21:39-49. doi: 10.3233/BEN-2009-0234\n1. Sarazin M, Chauvir\u00e9 V, Gerardin E,\net al\n. The amnestic syndrome of hippocampal type in Alzheimer's disease: An MRI study.\nJ Alzheimers Dis\n. 2010;22(1):285-294. doi: 10.3233/JAD-2010-091150\n1. Birks J, Craig D. Galantamine for vascular cognitive impairment.\nCochrane Database Syst Rev\n. 2006;2006(1):CD004746. doi: 10.1002/14651858.CD004746\n1. Reisberg B, Doody R, St\u00f6ffler A,\net al\n. Memantine in moderate-to-severe Alzheimer's disease.\nN Engl J Med\n. 2003;348(14):1333-1341. doi: 10.1056/NEJMOA013128\n1. Van Dyck CH, Swanson CJ, Aisen P,\net al\n. Lecanemab in early Alzheimer's disease.\nN Engl J Med\n. 2023;388:9-21. doi: 10.1056/NEJMoa2212948\n1. Olazar\u00e1n J, Reisberg B, Clare L,\net al\n. Nonpharmacological therapies in Alzheimer's disease: A systematic review of efficacy.\nDement Geriatr Cogn Disord.\n2010;30:161-178. doi: 10.1159/000316119\n1. Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease.\nNat Rev Neurol.\n2019;15(2):73-88. doi: 10.1038/S41582-018-0116-6", "doc_items_refs": ["#/texts/209", "#/texts/210", "#/texts/211", "#/texts/212", "#/texts/213", "#/texts/214", "#/texts/215"], "page_nos": [], "uuid": "776b4140-4cf7-44b2-b420-553b47b71465"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 20, "source_chunk_idxs": [20], "num_tokens": 479, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Sevigny J, Chiao P, Bussi\u00e8re T,\net al\n. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease.\nNature\n. 2016;537(7618):50-56. doi: 10.1038/NATURE19323\n1. Brodtmann A, Darby D, Oboudiyat C,\net al\n. Assessing preparedness for Alzheimer disease-modifying therapies in Australasian health care systems.\nMed J Aust\n. 2023;218(6):247-249. doi: 10.5694/MJA2.51880\n1. Budd Haeberlein S, Aisen PS, Barkhof F,\net al\n. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease.\nJ Prev Alzheimer's Dis.\n2022;9(2):197-210. doi: 10.14283/JPAD.2022.30\n1. Dhillon S. Aducanumab: First approval.\nDrugs\n. 2021;81(12):1437-1443. doi: 10.1007/S40265-021-01569-Z\n1. Alexander GC, Karlawish J. The problem of aducanumab for the treatment of Alzheimer disease.\nAnn Intern Med\n. 2021;174(9):1303-1304. doi: 10.7326/M21-2603\n1. Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.\nAlzheimers Res Ther\n. 2021;13(1):98. doi: 10.1186/S13195-021-00838-Z\n1. Hershey LA, Tarawneh R. Clinical efficacy, drug safety, and surrogate endpoints: Has aducanumab met all of its expectations?\nNeurology\n. 2021;97(11):517-518. doi: 10.1212/WNL.0000000000012453", "doc_items_refs": ["#/texts/216", "#/texts/217", "#/texts/218", "#/texts/219", "#/texts/220", "#/texts/221", "#/texts/222"], "page_nos": [], "uuid": "de86ea47-72df-4f7f-bfd9-ee764591f484"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 21, "source_chunk_idxs": [21], "num_tokens": 452, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: Appropriate use recommendations.\nJ Prev Alzheimers Dis\n. 2021;8:398-410. doi: 10.14283/jpad.2021.41\n1. S\u00f6derberg L, Johannesson M, Nygren P,\net al\n. Lecanemab, aducanumab, and gantenerumab- binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for.\nNeurotherapeutics\n. 2023;20:195-206. doi: 10.1007/s13311-022-01308-6\n1. FDA Grants Accelerated Approval for Alzheimer's\n. Google Scholar. Available from: https://scholar.google.com/scholar?hl=en&amp;as\\_sdt=0%2c5&amp;q=12.%09fda+grants+accelerated+approval+for+alzheimer%e2%80%99s+drug+%282023%29+us+food+and+drug+administration+available+t%3a+https%3a%2f%2fwww.fda.gov%2fdrugs%2fnews+eventshumandrugs%2ffdaapproves/treatment/adults/alzheimers+disease+%28accessed+on+july+05%2c+2024%29.&amp;btng=#d=gs\\_cit&amp;t=1746172558266&amp;u=%2fscholar%3fq%3dinfo%3ax96l0erloqj%3ascholar.google.com%2f%26output%3dcite%26scirp%3d0%26hl%3den [Last accessed on 2025 May 01].", "doc_items_refs": ["#/texts/223", "#/texts/224", "#/texts/225"], "page_nos": [], "uuid": "88b7f255-6757-4226-a363-f31531b32624"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 22, "source_chunk_idxs": [22], "num_tokens": 475, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Swanson CJ, Zhang Y, Dhadda S,\net al\n. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody.\nAlzheimers Res Ther\n. 2021;13(1):80. doi: 10.1186/S13195-021-00813-8\n1. Fatima R, Khan Y, Maqbool M,\net al\n. Amyloid-\u03b2 clearance with monoclonal antibodies: Transforming Alzheimer's treatment.\nCurr Protein Pept Sci\n. 2025;26:515-545. doi: 10.2174/0113892037362037250205143911\n1. Loeffler DA. Antibody-mediated clearance of brain amyloid-\u03b2: Mechanisms of action, effects of natural and monoclonal anti-A\u03b2 antibodies, and downstream effects.\nJ Alzheimers Dis Rep.\n2023;7(1):873-899. doi: 10.3233/ADR-230025\n1. Pleen J, Townley R. Alzheimer's disease clinical trial update 2019-2021.\nJ Neurol\n. 2022;269(2):1038-1051. doi: 10.1007/S00415-021-10790-5\n1. DeMattos RB, Lu J, Tang Y,\net al\n. A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer's disease mice.\nNeuron.\n2012;76(5):908-920. doi: 10.1016/J.NEURON.2012.10.029\n1. Thussu S, Naidu A, Manivannan S, Grossberg GT. Profiling aducanumab as a treatment option for Alzheimer's disease: An overview of efficacy, safety and tolerability.\nExpert Rev Neurother\n. 2024;24:1045-1053. doi: 10.1080/14737175.2024.2402058", "doc_items_refs": ["#/texts/226", "#/texts/227", "#/texts/228", "#/texts/229", "#/texts/230", "#/texts/231"], "page_nos": [], "uuid": "0a02d231-3927-45b7-93e2-c93fce6ea14c"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 23, "source_chunk_idxs": [23], "num_tokens": 486, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Navitsky M, Joshi AD, Kennedy I,\net al\n. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the centiloid scale.\nAlzheimers Dement.\n2018;14:1565-1571. doi: 10.2967/JNUMED.117.198389\n1. Li X, Tsolis KC, Koper MJ,\net al\n. Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease.\nAlzheimers Dement.\n2021;17(6):946-958. doi: 10.1002/ALZ.12345\n1. Leventhal SS, Bisom T, Clift D,\net al\n. Antibodies targeting the Crimean-Congo hemorrhagic fever virus nucleoprotein protect via TRIM21.\nNat Commun.\n2024;15:9236. doi: 10.1038/s41467-024-53362-7\n1. Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21).\nProc Natl Acad Sci.\n2010;107(46):19985-19990. doi: 10.1073/PNAS.1014074107\n1. James LC, Keeble AH, Khan Z, Rhodes DA, Trowsdale J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function.\nProc Natl Acad Sci.\n2007;104(15):6200-6205. doi: 10.1073/PNAS.0609174104\n1. Manocha GD, Mishra R, Sharma N, Kumawat KL, Basu A, Singh SK. Regulatory role of TRIM21 in the type-I interferon pathway in Japanese encephalitis virus-infected human microglial cells.\nJ Neuroinflammation.\n2014;11(1):24. doi: 10.1186/1742-2094-11-24)", "doc_items_refs": ["#/texts/232", "#/texts/233", "#/texts/234", "#/texts/235", "#/texts/236", "#/texts/237"], "page_nos": [], "uuid": "eeafe536-1660-47f5-bda1-09f424e69b2d"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 24, "source_chunk_idxs": [24], "num_tokens": 439, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. McEwan WA, Hauler F, Williams CR,\net al\n. Regulation of virus neutralization and the persistent fraction by TRIM21.\nJ Virol.\n2012;86(16):8482-8491. doi: 10.1128/JVI.00728-12\n1. McEwan WA, Falcon B, Vaysburd M,\net al\n. Cytosolic fc receptor TRIM21 inhibits seeded tau aggregation.\nProc Natl Acad Sci.\n2017;114(3):574-579. doi: 10.1073/PNAS.1607215114\n1. Zeng J, Santos A, Mukadam A,\net al\n. Target-induced clustering activates trim-away of pathogens and proteins.\nNat Struct Mol Biol\n. 2021;28:278-289. doi: 10.1038/s41594-021-00560-2\n1. Miller LV, Papa G, Vaysburd M,\net al\n. Co-opting templated aggregation to degrade pathogenic tau assemblies and improve motor function.\nCell\n. 2024;187:5967-5980.e17. doi: 10.1016/j.cell.2024.08.024\n1. Benn J, Cheng S, Keeling S,\net al\n. Aggregate-selective removal of pathological tau by clustering-activated degraders.\nScience.\n2024;385(6712):1009-1016. doi: 10.1126/SCIENCE.ADP5186\n1. Dupr\u00e9 E, Danis C, Arrial A,\net al\n. Single domain antibody fragments as new tools for the detection of neuronal tau protein in cells and in mice studies.\nACS Chem Neurosci\n. 2019;10(9):3997-4006. doi: 10.1021/ACSCHEMNEURO.9B00217", "doc_items_refs": ["#/texts/238", "#/texts/239", "#/texts/240", "#/texts/241", "#/texts/242", "#/texts/243"], "page_nos": [], "uuid": "1471f373-0580-4916-bd9c-09d66dc83eff"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 25, "source_chunk_idxs": [25], "num_tokens": 494, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Hong JP, Chen WF, Nguyen DH, Xie Q. A proposed role for lymphatic supermicrosurgery in the management of Alzheimer's disease: A primer for reconstructive microsurgeons.\nArch Plast Surg\n. 2025;52(2):96-103. doi: 10.1055/A-2513-4313\n1. Iliff JJ, Wang M, Liao Y,\net al\n. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid \u03b2.\nSci Transl Med\n. 2012;4(147):147ra111. doi: 10.1126/SCITRANSLMED.3003748\n1. Sandrone S, Moreno-Zambrano D, Kipnis J, Van Gijn J. A (delayed) history of the brain lymphatic system.\nNat Med\n. 2019;25:538-540. doi: 10.1038/s41591-019-0417-3\n1. Li W, Chen D, Liu N, Luan Y, Zhu S, Wang H. Modulation of lymphatic transport in the central nervous system.\nTheranostics.\n2022;12:1117-1131. doi: 10.7150/thno.66026\n1. Proulx ST. Sciences SPC and ML, 2021 undefined. Cerebrospinal fluid outflow: A review of the historical and contemporary evidence for arachnoid villi, perineural routes, and dural lymphatics.\nCell Mol Life Sci\n. 2021;78(6): 2429-2457. doi: 10.1007/S00018-020-03706-5\n1. Chen JY, Zhao DW, Yin Y,\net al\n. Deep cervical lymphovenous anastomosis (LVA) for Alzheimer's disease: Microsurgical procedure in a prospective cohort study.\nInt J Surg\n. 2025;111:4211-4221. doi: 10.1097/JS9.0000000000002490", "doc_items_refs": ["#/texts/244", "#/texts/245", "#/texts/246", "#/texts/247", "#/texts/248", "#/texts/249"], "page_nos": [], "uuid": "c4ad6e78-9b6f-4fd4-a2b1-d0e631931876"}
{"doc_id": "2025__Neurodegeneration_in_Alzheimers_disease_A_narrative_review_of_mechanistic_insigh__W4413867325", "source_path": "<redacted:source_path>", "chunk_id": 26, "source_chunk_idxs": [26], "num_tokens": 372, "text": "Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches\n1. Ma YN, Wang Z, Tang W. Deep cervical lymphaticovenous anastomosis in Alzheimer's disease: A promising frontier or premature enthusiasm?\nBiosci Trends.\n2025;19(2):144-149. doi: 10.5582/bst.2025.01108\nPrevious article in this issue\nNext article in this issue\nCite This Article Md. Nazmul Hossain, Rabeya Sultana Badhon, Mohammad Shahangir Biswas, Munna Kumar Podder, Suronjit Kumar Roy, Rubait Hasan, Md. Moyen Uddin Pk . Neurodegeneration in Alzheimer's disease: A narrative review of mechanistic insights and emerging therapeutic approaches.\nAdvanced Neurology\n025160040.\nhttps://doi.org/10.36922/AN025160040\nEndNote(RIS) BibTeX RefMan Refworks Cancel Save Model Title 1 of 0 Cancel Save Share Copy Cancel Save Share Back to top Advanced Neurology, Electronic ISSN: 2810-9619 Print ISSN: 3060-8589, Published by AccScience Publishing\nHome\nInformation\nAbout\nSearch\nPublisher's Core Philosophy AccScience Publishing removes barriers to science and knowledge access. Contact Us A 9 Raffles Place, Republic Plaza 1 #06-00 Singapore 048619 T +65 8182 1586 E editorial@accscience.com\nTerms &amp; Conditions\nPrivacy Policy\nCookies Policy\nDisclaimer \u00a9 2025 AccScience Publishing, except Open Access articles We use cookies on our website to ensure you get the best experience.\nRead more about our cookies\nhere\nAccept", "doc_items_refs": ["#/texts/250", "#/texts/251", "#/texts/252", "#/texts/253", "#/texts/254", "#/texts/255", "#/texts/256", "#/texts/257", "#/texts/258", "#/texts/259", "#/texts/260", "#/texts/261", "#/texts/262", "#/texts/263", "#/texts/264", "#/texts/265", "#/texts/266", "#/texts/267", "#/texts/268", "#/texts/269"], "page_nos": [], "uuid": "3de458e6-e155-4dde-a125-15ece1dec6d0"}
